Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 9086 results
Found 9086 results.

AIDS Dementia Complex

Yiannoutsos CT, Nakas CT, Navia BA. "Assessing multiple-group diagnostic problems with multi-dimensional receiver operating characteristic surfaces: application to proton MR Spectroscopy (MRS) in HIV-related neurological injury." Neuroimage. 2008;40(1):248-55.
Coban H, Robertson K, Smurzynski M, et al. "Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen." AIDS. 2017;31(11):1565-1571.
Schifitto G, Zhang J, Evans SR, et al. "A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment." Neurology. 2007;69(13):1314-21.
Paul RH, Yiannoutsos CT, Miller EN, et al. "Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity." J Neuropsychiatry Clin Neurosci. 2007;19(3):283-92.
Robertson K, Kopnisky K, Hakim J, et al. "Second assessment of NeuroAIDS in Africa." J. Neurovirol.. 2008;14(2):87-101.
Robertson K, Jiang H, Kumwenda J, et al. "Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study." Clin. Infect. Dis.. 2012;55(6):868-76.
Schifitto G, Yiannoutsos CT, Ernst T, et al. "Selegiline and oxidative stress in HIV-associated cognitive impairment." Neurology. 2009;73(23):1975-81.
Robertson KR, Su Z, Margolis DM, et al. "Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort." Neurology. 2010;74(16):1260-6.
Sacktor N, Miyahara S, Evans S, et al. "Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment." J. Neurovirol.. 2014;20(6):620-6.
Zhao Y, Navia BA, Marra CM, et al. "Memantine for AIDS dementia complex: open-label report of ACTG 301." HIV Clin Trials. 2010;11(1):59-67.

AIDS Vaccines

Li JZ, Heisey A, Ahmed H, et al. "Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study." AIDS. 2014;28(18):2649-57.
Li JZ, Brumme CJ, Lederman MM, et al. "Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial." PLoS ONE. 2012;7(3):e34134.
Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. "What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials." J. Infect. Dis.. 2003;188(2):179-93.
Li JZ, Brumme ZL, Brumme CJ, et al. "Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial." J. Infect. Dis.. 2011;203(7):976-83.
Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR. "Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption." J. Acquir. Immune Defic. Syndr.. 2012;61(1):19-22.
Jacobson JM, Zheng L, Wilson CC, et al. "The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection." J. Acquir. Immune Defic. Syndr.. 2016;71(2):163-71.
Schooley RT, Spritzler J, Wang H, et al. "AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein." J. Infect. Dis.. 2010;202(5):705-16.

Pages